Join to access to all OVN content. Join for Free
Product Safety and its Role in Medical Affairs
Medical Safety Product Safety MSLs Communication AI in Healthcare Regulatory Changes

Product Safety and its Role in Medical Affairs


Share This Article


Summary

This week's guest is Juan Daccach, MD, VP Global Product Safety at Merz Aesthetics who discusses Safety and its role in Medical/Product Safety and the interaction between safety physicians and medical affairs physicians (for both pharma and device)

Key Points

  • Understanding the nuances of medical and product safety is crucial for MSLs to effectively communicate with healthcare providers and ensure patient safety.
  • MSLs play a pivotal role in bridging the gap between field observations and internal safety teams by reporting adverse events and potential product issues promptly.
  • The evolving landscape of AI, machine learning, and combination products is reshaping the medical device and pharma industries, emphasizing the need for MSLs to stay informed about regulatory changes and technological advancements.

Click for Source
Medical Safety, Product Safety, MSLs Communication, AI in Healthcare, Regulatory Changes

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
OVN Avatar Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard

Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology

Podcast
The Struggle With KOL Access in Todays World
Partner Avatar MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper

The Struggle With KOL Access in Todays World

Podcast
The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges
Partner Avatar MSL Talk: Tom Caravela, Stephanie Otis

The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Explore OVN